Jill Genua, MD
Colon & Rectal Surgery · Delmar, NYNPI 1215979620
Payments from drug & device makers
What this record shows
This record is dominated by education: $16,085 of the $19,678 with a category attached, or 81.7%. Intuitive Surgical accounts for 95.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $17,535 and has fallen 98.3% since, to $296 in 2024. Among colon & rectal surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $491.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$19K
- AbbVie$410
- Medtronic$173
- Johnson & Johnson$133
- Fresenius Kabi USA, LLC$123
- TEI Biosciences Inc$45
- plus $35 from 2 others
What the payments were for
- Travel & lodging$2,47913%
- Food & beverage$1,1146%
- Education$16,08582%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 29 | $18,758 |
| AbbVie(2 entities) | 4 | $410 |
| Medtronic | 1 | $173 |
| Johnson & Johnson | 2 | $133 |
| Fresenius Kabi USA, LLC | 1 | $123 |
| TEI Biosciences Inc | 1 | $45 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Palette Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$16,000
- Da Vinci Surgical System$2,422
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$283
- EEA$173
- Smoflipid$123
- Echelon Powered Circular$108
- HARMONIC Product Family$108
- STRATAFIX$108
How this compares
$19,678 in reported general payments places this provider in the 90th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 39 | $37,939 |
| Levetiracetam | 44 | $4,485 |
| Pantoprazole Sodium | 81 | $2,747 |
| FamotidineFamotidine/Pf | 107 | $1,828 |
| Furosemide | 40 | $1,693 |
| Sodium Chloride0.9 % Sodium Chloride | 118 | $1,254 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $1,169 |
| Magnesium Sulfate | 39 | $682 |
| SmoflipidFat Emul/Soy/Mct/Oliv/Fish Oil | 19 | $623 |
| Vancomycin Hcl | 24 | $473 |
| Ondansetron HclOndansetron Hcl/Pf | 31 | $435 |
| Famotidine | 20 | $222 |
| Sodium ChlorideSodium Chloride 0.45 % | 24 | $211 |
| Diphenhydramine Hcl | 36 | $205 |
| Doxycycline Hyclate | 13 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius Kabi USA, LLCSodium Chloride, Magnesium Sulfate, Smoflipid, Sodium Chloride | $123 | $2,770200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 colon & rectal surgery providers in New York.
Other colon & rectal surgery in Delmar
- David RivadeneiraWoodbury$271K
- Jerald WishnerMount Kisco$246K
- Sanghyun KimNew York$154K
- Ziad KronfolWest Nyack$81K
- Lynn OconnorHuntington$63K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- Stephen RauhRochester$37K
- Evelyn IrizarryBronx$26K
- David SchwartzbergNew York$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.